Vasalgel Male Contraceptive

Promotional graphic for Vasalgel Male Contraceptive

Plan A male contraceptive 

The Parsemus Foundation and its social venture subsidiary Revolution Contraceptives, LLC have partnered with NEXT Life Sciences to continue development of the Vasalgel male contraceptive. NEXT Life Sciences announced launch of Plan A birth control for men, using the Vasalgel technology.

Vasalgel male contraceptive has a new home

After a decade of research on Vasalgel, the Parsemus Foundation determined that the reversible, long-lasting contraceptive for men was ready to advance to the next level. The search began for an organization with the resources needed to lead the project to the marketplace, including clinical trials and regulatory review. The Parsemus Foundation selected NEXT Life Sciences, Inc. as that partner. NEXT Life Sciences’ mission is to develop and distribute medical technology that empowers people to choose when and whether to have a child. 

NEXT Life Sciences announced its launch of the product called Plan A, using the Vasalgel technology for male contraception.  The NEXT team expects Plan A to be available to the public in 2026.

For more information, see the NEXT Life Sciences and Plan A websites.

Vasalgel Male Contraceptive partners with NEXT

How to stay engaged with Vasalgel

Stay Connected

Visit the NEXT Life Sciences Plan A website

  • Visit the NEXT LifeSciences Plan A website to get more information on Vasalgel.

What People Are Saying

Reproductive Health News

We’re sorry, you are not eligible for the nationwide COVID-OUT or ACTIV-6 studies, but you may be eligible for other federal trials:

And if you don’t find a match there, this slightly more complex clinical trials finder includes studies sponsored by companies as well:

Trials Today